Xgeva在中国怎么买呢？

It was first approved in the United States in 2010 for the prevention of bone-related events in adults with bone metastases from solid tumors. It was also approved in Europe in 2011 for the same indication. Data from clinical trials. A total of 305 adult and adolescent patients with GCTB who either had recurrent disease or were ineligible for surgical resection were recruited. The FDA stated that among these 187 patients, tumor shrinkage was observed in 47 patients after an average of 3 months, and 51% of patients had an objective response that lasted for at least 8 months. The data also showed that GCTB re-grew in 3 patients whose tumors shrank during an average follow-up of 20 months.

The safety profile of Xgeva in patients with GCTB "is similar to what has been reported in previous studies of patients with bone metastases, and is similar in skeletally mature adolescents and adults." Because denosumab is a monoclonal antibody that targets RANKL and may harm the fetus, women of childbearing potential are cautioned to use "highly effective contraception" while using denosumab.

How to buy Xgeva treatment effect? How to buy Xgeva in China?

It is understood that Xgeva has been launched in China. On May 23, 2019, China’s National Medical Products Administration announced conditional approval of the import registration application for (Xgeva) denosumab injection (English name: Denosumab Injection). The drug will be used to treat adults and skeletally mature adolescent patients with unresectable giant cell tumors of bone or whose surgical resection may result in severe functional impairment.

It is a prescription drug. To purchase Xgeva, patients must rely on a doctor's prescription and apply it in sufficient dosage and for a sufficient course of treatment. Your symptoms may be relieved before the condition is completely controlled, but do not reduce the dosage or stop taking the medicine easily. However, in comparison, the price of Xgeva launched in Türkiye is more advantageous than the domestic price.